Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Cognitive Late Effects in Childhood Cancer Survivors
NCT00255138Phase 3Withdrawn
- Sponsor
- Temple University
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atomoxetine in cognitive dysfunction, sponsored by Temple University. Planned start Nov 2005; status: withdrawn.
02
Drugs
atomoxetine
03
Conditions
cognitive dysfunction
Beyond the preview
Go deeper on NCT00255138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255138.